切换至 "中华医学电子期刊资源库"
高级检索
中华乳腺病杂志(电子版)

中华乳腺病杂志(电子版) ›› 2019, Vol. 13 ›› Issue (04) : 225 -233. doi: 10.3877/cma.j.issn.1674-0807.2019.04.007

所属专题： 文献；

论著

乳腺癌HOXA4基因甲基化的检测及其临床意义
李少英1,†(), 麦慧芬1, 黎桂森1, 梁碧婵1, 姜敏1, 甄建新2, 王辉林2, 陈少君3   
  1. 1. 518133　暨南大学附属深圳市宝安区妇幼保健院乳腺科
    2. 518133　暨南大学附属深圳市宝安区妇幼保健院中心实验室
    3. 518000　深圳市妇幼保健院乳腺科
  • 收稿日期:2019-03-19 出版日期:2019-08-01
  • 通信作者: 李少英
  • 基金资助:
    深圳市科技计划资助项目(JCYJ20150403105513703); 广东省科技计划资助项目(20150211); 深圳市三名工程项目出生缺陷防治研究与转化团队项目(201406007)

Detection of aberrant HOXA4 gene methylation in breast cancer and its clinical significance

Shaoying Li1,†(), Huifen Mai1, Guisen Li1, Bichan Liang1, Min Jiang1, Jianxin Zen2, Huilin Wang2, Shaojun Chen3   

  1. 1. Department of Breast Diseases, Bao’an Maternal and Child Health Hospital, Jinan University, Shenzhen 518133
    2. Central Laboratory, Bao’an Maternal and Child Health Hospital, Jinan University, Shenzhen 518133
    3. Department of Breast Diseases, Shenzhen Maternal and Child Health Hospital, Shenzhen 518000, China
  • Received:2019-03-19 Published:2019-08-01
  • Corresponding author: Shaoying Li
  • About author:
    Corresponding author: Li Shaoying, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

李少英, 麦慧芬, 黎桂森, 梁碧婵, 姜敏, 甄建新, 王辉林, 陈少君. 乳腺癌HOXA4基因甲基化的检测及其临床意义[J/OL]. 中华乳腺病杂志(电子版), 2019, 13(04): 225-233.

Shaoying Li, Huifen Mai, Guisen Li, Bichan Liang, Min Jiang, Jianxin Zen, Huilin Wang, Shaojun Chen. Detection of aberrant HOXA4 gene methylation in breast cancer and its clinical significance[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2019, 13(04): 225-233.

目的

探讨乳腺癌患者HOXA4基因启动子甲基化的情况及其与临床病理特征的相关性。

方法

运用NEBNext? Ultra? RNA Library Prep Kit for Illumina?进行基因表达芯片测序，运用随机数字表法选择2014年深圳市宝安区妇幼保健院收治的9例乳腺癌患者，分析癌组织与相应癌旁组织异常差异表达的基因。运用Illumina Infinium HD Methylation 450K Assay进行DNA甲基化测序，分析乳腺癌甲基化差异基因。基于肿瘤基因组图谱(The Cancer Genome Atlas，TCGA)数据库信息，分析乳腺癌的差异表达基因和差异甲基化基因。挑选显著高甲基化与低表达的基因，结合生物信息学，确定HOXA4为候选基因。运用随机数字表法收集2014—2017年深圳市宝安区妇幼保健院收治的另外86例乳腺癌患者，采用焦磷酸测序法和RT-PCR，检测乳腺癌组织及其癌旁乳腺组织中HOXA4基因甲基化率和mRNA表达，用Fisher确切概率法分析甲基化率与患者临床病理特征的关系。用Cox比例风险模型进行风险因素的单因素和多因素分析。分别用0、0.5、1、5、10、20 μmol/L的甲基化抑制剂RG108处理乳腺癌MCF-7细胞5 d后，检测HOXA4 mRNA的表达。

结果

基因表达数据芯片分析发现在乳腺癌组织中有1 680个显著上调的基因和1 249个下调基因，整体水平上在不同区域乳腺癌患者甲基化水平较癌旁组织高(P均<0.001)。86例乳腺癌组织中HOXA4基因的甲基化率为94% (81/86)，其中，30例高甲基化，52例低甲基化；而在对应癌旁组织中，HOXA4基因甲基化率为57%(49/86)，其中49例低甲基化，无高甲基化(P<0.001)。有HOXA4甲基化组的癌组织样本中HOXA4 mRNA表达低于无HOXA4甲基化组的癌组织样本(P＝0.003)。HOXA4基因甲基化水平与乳腺癌淋巴结转移、ER表达有关(P＝0.039、0.017)。单因素分析结果显示患者的TNM分期、组织学分级、淋巴结转移及HOXA4甲基化是DFS的危险因素(RR＝4.008，95%CI＝1.296～12.393，P＝0.016；RR＝10.111，95%CI＝2.607～39.217，P＝0.001；RR＝4.588，95%CI＝1.201～17.523，P＝0.026；RR＝1.051，95%CI＝1.007～1.098，P＝0.024)。多因素分析显示组织学分级是乳腺癌患者DFS的独立预后因素(RR＝14.461，95%CI＝2.429～86.100，P＝0.003)。采用不同浓度的RG108来处理MCF-7细胞后，各组HOXA4 mRNA表达比较，差异有统计学意义(χ2＝4.472，P＝0.029)。

结论

HOXA4基因启动子甲基化在乳腺癌的发生、发展中起着重要作用，有潜力作为新的分子生物学指标，用于乳腺癌临床诊断。

关键词: 乳腺肿瘤, 基因，HOXA4, 甲基化
Objective

To investigate the methylation of HOXA4 in breast cancer patients and its correlation with clinicopathological characteristics.

Methods

NEBNext? Ultra? RNA Library Prep Kit for Illumina? was used for gene expression microarray and the screening of abnormally expressed genes in breast cancer tissues and adjacent breast tissues from 9 breast cancer patients (enrolled by a random number table)in Bao’an Maternal and Child Health Hospital in 2014. Illumina Infinium HD Methylation450K Assay was used for DNA methylation microarray and detection of differentially methylated genes in breast cancer. Then the differentially expressed genes and methylated genes in breast cancer were further explored based on The Cancer Genome Atlas (TCGA). The genes with significant hypermethylation and low expression were selected. Combined with bioinformatics, HOXA4 was identified as a candidate gene, with the potential for the detection of early breast cancer. The methylation and mRNA expression of HOXA4 gene in breast cancer tissues and adjacent breast tissues from 86 breast cancer patients (enrolled by a random number table)in Bao’an Maternal and Child Health Hospital from 2014 to 2017 were detected by pyrophosphoric acid sequencing and RT-PCR. And the correlation between HOXA4 mehtylation and the clinicopathological characteristics was also analyzed by the Fisher exact test. Cox proportional hazards model was used for univariate and multivariate analysis of risk factors. The breast cancer MCF-7 cells were treated with 0, 0.5, 1, 5, 10, 20 μmol/L methylation inhibitor RG108 for 5 days, then HOXA4 mRNA expression was detected.

Results

The gene expression microarray showed that 1 680 upregulated genes and 1 249 downregulated genes were determined in breast cancer tissue. The overall methylation levels in different regions of breast cancer tissues were significantly higher than those in adjacent tissues (All P<0.001). In 86 breast cancer patients, the methylation rate of HOXA4 gene was 95% (82/86) in breast cancer tissue(52 samples with low methylation and 30 with hypermethylation), 57% (49/86) in the corresponding adjacent tissues (49 samples with low methylation and none with hypermethylation) (χ2=4.779, P=0.029). The expression of HOXA4 mRNA in HOXA4 methylation group was significantly lower than that in non-methylation group (P=0.031). HOXA4 methylation was correlated with lymph node metastasis(P=0.039) and ER negative (P=0.017). Univariate analysis showed that TNM stage, histological grade, lymph node metastasis and HOXA4 methylation were risk factors for DFS (RR=4.008, 95%CI=1.296-12.393, P=0.016; RR=10.111, 95%CI=2.607-39.217, P=0.001; RR=4.588, 95%CI=1.201-17.523, P=0.026; RR=1.051, 95%CI=1.007-1.098, P=0.024). Multivariate analysis showed that histological grade was an independent prognostic factor for DFS in breast cancer patients (RR=14.461, 95%CI=2.429-86.100, P=0.003). After treatment with different concentrations of RG108, the expression of HOXA4 mRNA in MCF-7 cells was significantly different among six groups (χ2=4.472, P=0.029).

Conclusion

The methylation of HOXA4 plays an important role in the occurrence and development of breast cancer, which may serve as a novel molecular biological marker for clinical diagnosis of breast cancer.

Key words: Breast neoplasms, Gene, HOXA4, Methylation
表1 Cox比例风险回归模型变量赋值表
变量 变量赋值
年龄 <46岁＝0，≥46岁＝1
肿瘤大小 ≤20 mm＝0，>20 mm＝1
TNM分期 Ⅰ、Ⅱ期＝0，Ⅲ期＝1
组织学分级 1、2级＝0，3级＝1
淋巴结转移 无转移＝0，有转移＝1
ER 阴性＝0，阳性＝1
PR 阴性＝0，阳性＝1
HER-2 阴性＝0，阳性＝1
Ki67 <30%＝0，≥30%＝1
TP53 正常＝0，突变＝1
图1 9例乳腺癌组织与癌旁组织差异基因火山图
图2 9例样本的乳腺癌组织及癌旁组织中不同基因区域差异基因甲基化率比较
图3 TCGA数据库中的乳腺癌组织及癌旁组织不同基因区域的差异基因甲基化率比较
图4 9例样本的乳腺癌组织及癌旁组织中不同基因区域HOXA4基因甲基化率比较
图5 差异甲基化基因-差异表达基因-乳腺癌基因相互作用网络
表2 乳腺癌与癌旁乳腺组织中HOXA4基因甲基化情况
癌旁乳腺组织 乳腺癌 合计
有甲基化 无甲基化
有甲基化 49 0 49
无甲基化 32 5 37
合计 81 5 86
表3 乳腺癌HOXA4基因有无甲基化组的mRNA表达情况
组别 低表达 高表达
HOXA4甲基化 30 3
HOXA4无甲基化 0 3
表4 86例乳腺癌患者HOXA4基因甲基化与临床病理特征的关系
临床病理特征 例数 肿瘤组织甲基化例数(%) P值
年龄 ? ? ?
? < 46岁 38 38(100) 0.126
? ≥ 46岁 48 44(92)
淋巴结转移 ? ? ?
? 无 39 35(90) 0.039
? 有 47 47(100)
TNM分期 ? ? ?
? Ⅰ/Ⅱ期 60 56(93) 0.310
? Ⅲ期 26 26(100)
肿瘤大小 ? ? ?
? ≤20 mm 40 37(93) 0.334
? >20 mm 46 45(98)
组织学分级 ? ? ?
? 1～2级 52 48(92) 0.149
? 3级 34 34(100)
ER表达 ? ? ?
? 阴性 54 54(100) 0.017
? 阳性 32 28(88)
PR表达 ? ? ?
? 阴性 39 39(100) 0.123
? 阳性 47 43(91)
HER-2表达 ? ? ?
? 阴性 58 55(95) 1.000
? 阳性 28 27(96)
TP53突变 ? ? ?
? 正常 44 41(93) 0.616
? 突变 42 41(98)
Ki67表达 ? ? ?
? <30% 39 37(95) 1.000
? ≥30% 47 45(96)
表5 86例乳腺癌患者无瘤生存率的单变量分析结果
变量 回归系数 标准误 Wald值 P值 RR 95%置信区间
年龄 －0.598 0.559 1.142 0.285 0.550 0.184～1.647
肿瘤大小 1.213 0.625 3.766 0.052 3.364 0.988～11.451
TNM分期 1.388 0.576 5.812 0.016 4.008 1.296～12.393
组织学分级 2.314 0.692 11.192 0.001 10.111 2.607～39.217
淋巴结转移 1.523 0.684 4.965 0.026 4.588 1.201～17.523
ER －1.120 0.685 2.674 0.102 0.326 0.085～1.249
PR －0.916 0.566 2.624 0.105 0.400 0.132～1.212
HER-2 －0.074 0.596 0.015 0.902 0.929 0.289～2.989
Ki67 0.731 0.590 1.536 0.215 2.078 0.654～6.604
TP53 0.683 0.569 1.437 0.231 1.979 0.648～6.042
HOXA4甲基化 0.050 0.022 5.088 0.024 1.051 1.007～1.098
图6 不同浓度的甲基化抑制剂RG108处理后MCF-7细胞中HOXA4 mRNA的表达
[1]
Ghoncheh M, Mirzaei M, Salehiniya H. Incidence and mortality of breast cancer and their relationship with the human development index (HDI) in the world in 2012[J]. Asian Pac J Cancer Prev, 2015, 16(18):8439-8443.
[2]
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]．CA Cancer J Clin, 2013, 63(1):11-30.
[3]
Mannello F, Tonti GA, Simone P, et al. Iron-binding proteins and C-reactive protein in nipple aspirate fluids: role of Iron-driven inflammation in breast cancer microenvironment？[J]. Am J Transl Res, 2010, 3(1):100-113.
[4]
Balabram D, Turra CM, Gobbi H. Survival of patients with operable breast cancer (Stages Ⅰ－Ⅲ) at a Brazilian public hospital--a closer look into cause-specific mortality [J]．BMC Cancer, 2013,13:434.
[5]
Houssami N, Ciatto S, Martinelli F, et al. Early detection of second breast cancers improves prognosis in breast cancer survivors [J]. Ann Oncol, 2009, 20(9):1505-1510.
[6]
Dworkin AM, Huang TH, Toland AE. Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment [J]．Semin Cancer Biol, 2009, 19(3):165-171.
[7]
Karsli-Ceppioglu S, Dagdemir A, Judes G, et al. Epigenetic mechanisms of breast cancer: an update of the current knowledge[J]．Epigenomics, 2014, 6(6):651-664.
[8]
Guerrero-Preston R, Hadar T, Ostrow KL, et al. Differential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacity [J]．Oncol Rep, 2014, 32(2):505-512.
[9]
Yang R, Pfutze K, Zucknick M, et al. DNA methylation array analyses identified breast cancer-associated HYAL2 methylation in peripheral blood[J]. Int J Cancer, 2015, 136(8):1845-1855.
[10]
Heyn H, Carmona FJ, Gomez A, et al. DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker [J]. Carcinogenesis, 2013, 34(1):102-108.
[11]
Xiao CL, Mai ZB, Lian XL, et al. FANSe2: a robust and cost-efficient alignment tool for quantitative next-generation sequencing applications [J]．PLoS One, 2014, 9(4):e94250.
[12]
Zhang G, Fedyunin I, Kirchner S, et al. FANSe: an accurate algorithm for quantitative mapping of large scale sequencing reads[J]. Nucleic Acids Res, 2012, 40(11):e83.
[13]
National Cancer Institute. The Cancer Genome Atlas Program[DB/OL]. [2019-03-10].

URL    
[14]
Conway J, Gehlenborg N. UpSetR: a more scalable alternative to Venn and Euler diagrams for visualizing intersecting sets [DB/OL]. [2019-03-10].

URL    
[15]
Powitzky ES, Khaitan L, Garrett CG, et al. Symptoms, quality of life, videolaryngoscopy, and twenty-four-hour triple-probe pH monitoring in patients with typical and extraesophageal reflux[J]. Ann Otol Rhinol Laryngol, 2003, 112(10):859-865.
[16]
Danhorn T, Yonug CR, Delong EF. Comparison of large-insert, small-insert and pyrosequencing libraries for metagenomic analysis[J]. ISME J, 2012, 6(11):2056-2066.
[17]
Eckhardt F, Lewin J, Cortese R, et al. DNA methylation profiling of human chromosomes 6, 20 and 22[J]. Nat Genet, 2006, 38(12):1378-1385.
[18]
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data [J]．Bioinformatics, 2010, 26(1):139-140.
[19]
Tang Q, Cheng J, Cao X, et al. Blood-based DNA methylation as biomarker for breast cancer: a systematic review [J]．Clin Epigenetics, 2016, 8:115.
[20]
Choi JY, James SR, Link PA, et al. Association between global DNA hypomethylation in leukocytes and risk of breast cancer[J]．Carcinogenesis,2009, 30(11):1889-1897.
[21]
Xu X, Gammon MD, Hernandez-Vargas H, et al. DNA methylation in peripheral blood measured by LUMA is associated with breast cancer in a population-based study[J]．FASEB J, 2012, 26(6):2657-2666.
[22]
Li SY, Wu HC, Mai HF, et al. Microarray-based analysis of whole-genmoe DNA methylation profiling in early detection of breast cancer[J]. J Cell Biochem, 2019, 120(1):658-670.
[23]
Musialik E, Bujko M, Kober P, et al. Promoter DNA methylation and expression levels of HOXA4, HOXA5 and MEIS1 in acute myeloid leukemia [J]. Mol Med Rep, 2015, 11(5):3948-3954.
[24]
Bhatlekar S, Addya S, Salunek M, et al. Identification of a developmental gene expression signature, including HOX genes, for the normal human colonic crypt stem cell niche: overexpression of the signature parallels stem cell over population during colon tumorigenesis[J]. Stem Cells Dev, 2014, 23(2):167-179.
[25]
Yamashita T, Tazawa S, Yawei Z, et al. Suppression of invasive characteristics by antisense introduction of overexpressed HOX genes in ovarian cancer cells [J]. Int J Oncol, 2006, 28(4):931-938.
[26]
Tholouli E, MacDemott S, Hoyland J, et al. Quantitative multiplex quantum dot in-situ hybridisation based gene expression profiling in tissue microarrays identifies prognostic genes in acute myeloid leukaemia[J]. Biochem Biophys Res Commun, 2012, 425(2):333-339.
[27]
Cheng S, Qian F, Huang Q, et al. HOXA4，down-regulated in lung cancer, inhibits the growth, motility and invasion of lung cancer cells [J]. Cell Death Dis, 2018, 9(5):465.
[28]
Gray S, Pandha HS, Michael A, et al. HOX genes in pancreatic development and cancer[J]. JOP, 2011, 12(3):216-219.
[29]
Fournier M, Lebert-Ghali CE, Krosl G, et al. HOXA4 induces expansion of hematopoietic stem cells in vitro and confers enhancement of pro-B-cells in vivo [J]. Stem Cells Dev, 2012, 21(1):133-142.
[30]
Elias MH, Baba AA, Husin A, et al. HOXA4 gene promoter hypermethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patients [J]．Biomed Res Int, 2013, 2013:129715.
[31]
Ayyanan A, Civenni G, Ciarloni L, et al. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism [J]. Proc Natl Acad Sci U S A, 2006, 103(10): 3799-3804.
[32]
Nagahata T, Shimada T, Harada A, et al. Amplification, up-regulation and over-expression of DVL-1, the human counterpart of the Drosophila disheveled gene, in primary breast cancers [J]．Cancer Sci, 2003, 94(6):515-518.
[33]
Zhang H, Zhang X, Wu X, et al. Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/β-catenin pathway[J]．Cancer Lett, 2012, 32(42): 106-113.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(06): 563-570.
[2] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[3] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[4] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[5] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[6] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[7] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[8] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[9] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[10] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[11] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[12] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[13] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[14] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[15] 孙晗, 于冰, 武侠, 周熙朗. 基于循环肿瘤DNA 甲基化的结直肠癌筛查预测模型的构建与验证[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 500-506.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号